Anti-Properdin Antibodies for Selective Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement-mediated disease treatments, particularly those targeting the alternative complement pathway, face challenges such as individual drug bioavailability or efficacy issues, safety concerns, and the need for disease-tailored therapeutic approaches, with limited approved therapeutics beyond anti-C5 agents like eculizumab.
Innovation Solution
Development of anti-properdin antibodies that selectively inhibit the alternative complement pathway while allowing the classical and lectin pathways to function, with modified FcγR binding to minimize ADCC activity and enhanced FcRn affinity for extended half-life, enabling reduced dosing frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-C5 agents like eculizumab are used to treat complement-mediated diseases, then disease treatment efficacy is improved, but the number of approved therapeutics remains limited and disease-tailored approaches are insufficient
Solution Approach 1:
The complement system is segmented into three distinct pathways (classical, lectin, and alternative), each with unique activation mechanisms and regulatory controls. The patent applies segmentation by developing pathway-specific inhibitors that target individual components (such as properdin for the alternative pathway, factor D for classical pathway, or MBL for lectin pathway), allowing disease-tailored treatment strategies that selectively block specific pathways based on their role in particular diseases.
Solution Approach 2:
Different diseases require different levels and types of complement inhibition. The patent applies local quality by matching specific complement pathway inhibitors to specific disease indications based on the pathogenic role of each pathway. For example, alternative pathway inhibition may be preferred for certain autoimmune conditions, while classical pathway inhibition may be更适合 for infections, allowing each treatment to have optimized local properties for its specific indication.
2Reliability
If complement pathway inhibition is strengthened to reduce tissue damage, then therapeutic efficacy is improved, but safety concerns increase due to excessive regulation of complement
Solution Approach 1:
By segmenting the complement inhibition strategy into pathway-specific approaches, the patent enables precise control over which complement components are blocked. This allows strengthening of inhibition in pathways that drive tissue damage while preserving activity in pathways that provide protective functions, thereby improving therapeutic efficacy without excessive safety risks.
Solution Approach 2:
The patent applies partial action by developing inhibitors that provide just enough blockage to achieve therapeutic effect without complete suppression of complement function. For example, pathway-specific inhibitors may be used at doses and durations optimized to achieve sufficient protection against tissue damage while maintaining enough complement activity for host defense, avoiding excessive inhibition that would cause safety problems.
3Object-affected harmful factors
If the alternative complement pathway is selectively inhibited to preserve immune defense, then safety is improved, but the complexity of selecting appropriate targets and dosing increases
Solution Approach 1:
The patent applies parameter changes by optimizing various characteristics of the alternative pathway inhibitors, including binding affinity, half-life, and dosing intervals. By modifying these parameters, the patent achieves effective alternative pathway inhibition with reduced dosing frequency and improved safety profile, making the therapeutic approach more manageable despite the complexity of target selection.
4Object-affected harmful factors
If antibody FcγR binding is modified to minimize ADCC activity, then safety is improved, but manufacturing and characterization complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the Fc region of the antibodies, specifically altering FcγR binding properties to minimize ADCC activity while maintaining other desirable characteristics. By optimizing parameters such as Fc glycosylation patterns, FcRn binding affinity, and FcγR interaction strengths, the patent achieves improved safety with manageable manufacturing and characterization requirements.
Data Source
AI summary
The present invention provides an antibody or antigen-binding portion thereof that can bind to properdin (factor P). The antibody of the current invention leads to selective inhibition of alternative complement pathway while allowing the classical and lectin pathways to continue. Further, the antibody of the present invention may have modified or reduced binding to FcγRs to minimize its ADCC activity. The present invention provide an antibody that comprises an amino acid sequence to minimise its CDC activity. The antibody according to the present invention has higher FcRn binding affinity and therefore the antibody according to the present invention may have long circulating half-life in the body of the patient and it can be given at a reduced dosing frequency. The antibody according to the present invention can further be used in the preparation of a drug for treating diseases through inhibition of alternative complement pathway.